Spike Protein News and Research

RSS

Antibodies from llamas may hold cure for novel coronavirus SARS-CoV-2

As scientists across the globe race to find an effective treatment for the novel coronavirus, a team of scientists believe that a four-year-old llama named Winter may hold the key to fight the coronavirus disease (COVID-19).

7 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

A new study published on the preprint server bioRxiv in April 2020 reports that low levels of specific immune cells, namely, CD8 T cells and NK cells, are linked to higher expression of the ACE2 molecule, which acts as a receptor for the CoV.

6 May 2020

How do betacoronaviruses evolve?

Researchers have worked on the evolution of the pathogenic strains of the betacoronaviruses including the SARS CoV-2 that has caused the COVID-19 pandemic.

6 May 2020

SARS-CoV-2 genome shows mutation hotspots and type-specific distribution

Now, a new study published on the preprint server bioRxiv reports on a large scale analysis of SARS-CoV-2 genomes and reveals a clonal geo-distribution and rich genetic variations.

5 May 2020

COVID-19 infection risk and outcomes explained by the cell receptor genetic variability

Genetic variants in the angiotensin‐converting enzyme 2 (ACE2) receptor, utilized by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for cell entry, are predicted to either encourage or inhibit interaction with viral proteins and subsequently contribute to genetic risk in coronavirus disease (COVID-19). This is the key finding of a new study available on the preprint server bioRxiv*.

5 May 2020

Loss of smell may be related to neuroinvasive propensity of SARS-CoV-2

The novel coronavirus has rapidly infected millions over the world in over 187 countries and territories, causing hundreds of thousands of deaths. One of the often-neglected and under-reported symptoms of the virus is the loss of the sense of smell or anosmia. Now, a new study out of Germany published on the preprint server medRxiv in April 2020 provides a quantified estimate of the magnitude of anosmia as a symptom of the coronavirus.

4 May 2020

Uncovering immune cell reactions in COVID-19

A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.

4 May 2020

New information on viral antigens could improve COVID-19 testing

Researchers in France and China have characterized antibody responses to a wide range of antigens present on severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) among patients with coronavirus disease 2019 (COVID-19).

4 May 2020

Study defines new starting points for therapy and vaccine research on coronavirus

The SARS coronavirus 2 (SARS-CoV-2) infects lung cells and is responsible for the COVID-19 pandemic. The viral spike protein mediates entry of the virus into host cells and harbors an unusual activation sequence.

4 May 2020

Study reveals variable sites in novel coronavirus SARS-CoV-2

Understanding the varying aggressiveness of SARS-CoV-2 may provide valuable data to trace its spread across populations. In the study, published on the preprint server BioRxiv, the researchers traced amino acid variants that possess high frequency in Europe, particularly in Italy, one of the hardest-hit countries.

4 May 2020

SARS-CoV-2 receptor ‘mimic' could prevent COVID-19

Researchers from Italy have developed an exciting new peptide drug that could potentially prevent the coronavirus from infecting people’s cells. The paper, published on the preprint server bioRxiv* in April 2020, describes a small molecule that can bind to and block the attachment site on the virus spike protein, preventing its entry into the host cell.

4 May 2020

Research detects a more dangerous SARS-CoV-2 mutation

A new study published on the preprint server bioRxiv in May 2020 reports the setting up of a system to help track new mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is behind the current COVID-19 pandemic. This will help analyze mutations to find and track the spread of those that are most likely to increase the pathogenicity of the virus, either by making it easier to transmit or by enhancing its resistance to treatment.

4 May 2020

Low molecular weight heparins inhibit SARS-CoV-2 cell invasion

A recent paper available on the preprint server bioRxiv* reports preliminary data on the ability of low molecular weight heparins to interact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), elicit structural changes in its key proteins and subsequently halt cell invasion.

3 May 2020

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta Group plc is pleased to announce that it has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test.

From Avacta Life Sciences Ltd. 1 May 2020

Spike protein analysis from India's first SARS-CoV-2

A new study published on the preprint server bioRxiv analyzes viral spike protein sequences from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in West Bengal, India, comparing them with sequences from other Indian states and Wuhan, China.

30 Apr 2020

New database catalogs peptides that may halt SARS-CoV-2 cell infection

In the quest for a highly specific and tailored treatment strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recent publication available on the preprint server bioRxiv describes a repository of designed peptides that interfere with the early stages of viral invasion process.

30 Apr 2020

Testing sewage could be useful in monitoring COVID-19 circulation in the population

Researchers in Italy have demonstrated the potential value of sewage system monitoring for studying trends in the circulation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Apr 2020